Shares of Wave Life Sciences plunged 12.5% to $5.31 on August 11, as Wall Street punished the clinical-stage biotech for a second-quarter revenue miss so severe it forced analysts to slash full-year forecasts. The selloff raises a pointed question: with cash draining fast and no approved products, how long will investors fund the company's ambitious drug pipeline on faith alone?
Revenue Came in at a Fraction of What Wall Street Expected. Wave posted just $2.3 million in quarterly revenue — versus the $7.65 million analysts had forecast — a miss of roughly 70%. That figure was down from $8.7 million a year earlier, a 73.7% year-over-year collapse. Nearly all of Wave's revenue comes from a collaboration deal with pharmaceutical giant GSK, and the drop signals that milestone-dependent income is inherently lumpy and unpredictable. Analysts responded by cutting the 2026 full-year revenue estimate to $52 million from $59 million and trimming the consensus price target 13% to $19.06.
Losses Are Widening, Not Shrinking. The net loss ballooned to $69.4 million, up from $50.5 million in the same quarter last year.
R&D spending hit $51.3 million, up from $43.5 million a year ago , as Wave pushed deeper into trials for its obesity and liver-disease programs. The company burned through roughly $111 million in the first half of 2026 alone.
The Cash Runway Buys Time — But Not Forever. Wave held $490.6 million in cash and investments as of June 30, providing a runway into the third quarter of 2028. That gives management roughly two years to hit clinical milestones or secure a partnership, but at the current burn rate, there is no margin for delays. Management expects milestone payments from GSK in the second half of 2026, though notably these are excluded from cash runway projections.
Analysts Still Believe — But the Gap Between Hope and Price Is Enormous. Seventeen analysts maintain a "Strong Buy" consensus with an average price target of $20.29 — nearly four times today's price. That disconnect reflects bets on Wave's obesity drug program and a potential FDA fast-track decision expected this summer. Yet the stock's freefall shows the market demands proof, not promise.